Cores/Service Centers
Resource laboratories, formerly known as core facilities, have evolved beyond providing routine technical services at the University of Pennsylvania. They now play a central role in enabling complex, problem-driven research by offering advanced scientific and technological expertise, as well as facilitating the adoption of new methodologies.
In support of this mission, the Department of Pathology and Laboratory Medicine is home to several resource laboratories that provide a strong infrastructure for the development of academic programs and the expansion of web-based training systems. These efforts are further strengthened by a commitment to regulatory consistency and the strategic pursuit of external funding opportunities.
Individual researchers are urged to acknowledge all resource laboratories that contributed to their work in publications, citing each facility by name (e.g., Flow Cytometry and Cell Sorting Resource Laboratory, University of Pennsylvania).
Path BioResource (PBR)
Path BioResource (PBR) was created by the Department of Pathology and Laboratory Medicine to provide administrative support to the departmentally-based shared resource laboratories. Through partnering with the School of Medicine administration, as well as Centers and Institutes within the University community, Path BioResource seeks to provide all investigators access to high quality, cost-effective advanced technology services as well as the scientific expertise to use these technologies effectively in their research efforts.
Path BioResource is the administrative group comprised of the Departmental cores listed below.
Contacts
Jonni S. Moore, PhD
Executive Director, Path BioResource
Tel: 215-898-6853
MooreJ@pennmedicine.upenn.edu
Path BioResource Help Desk: 215-573-2958 or 215-573-0735
Departmental cores/service centers
The Department of Pathology and Laboratory Medicine has a longstanding commitment to supporting clinical and translational research through comprehensive laboratory services and faculty expertise. Department faculty collaborate with investigators as consultants, diagnostic specialists, and co-investigators, providing guidance in study design, implementation, and data analysis.
To streamline access to these resources, the Pathology Clinical Service Center (PCSC) was established to provide investigators with integrated blood- and tissue-based research services that support translational science across a broad range of disciplines.
The Anatomic Pathology Division (PCSC-AP) specializes in the analysis of human biospecimens and offers services including histology, immunohistochemistry, immunofluorescence, in situ hybridization, tissue microarray construction, molecular analysis, digital imaging, multispectral image analysis, and assay development.
The Transfusion Medicine & Therapeutic Pathology Division (PCSC-TM&TP) includes the Apheresis and Infusion Clinic, Stem Cell Laboratory, Blood Bank, and Penn Medicine Blood Donation Center. Operating in compliance with FDA regulations and accredited by AABB and FACT, the division provides expertise in the collection, processing, and reinfusion of cellular products, including mononuclear cell, whole blood, and plasma collections, elutriation, and supervised infusion therapies.
The Clinical Pathology Division (PCSC-CP) provides specialized analysis of blood and serum samples in chemistry, microbiology, coagulation, hematology, immunology, and molecular pathology. PCSC also supports IRB-approved studies through collection, storage, annotation, and analysis of research specimens.
Contacts
For projects in Anatomic Pathology: 215-349-8415
For projects in Transfusion Medicine and Therapeutics: 215-746-1195
For projects in Clinical Pathology: 215-662-3435
The Clinical Cell and Vaccine Production Facility (CVPF) renders bench-to-bedside translational medicine a reality. Equipped with state-of-the-art facilities, the CVPF manufactures cell and gene biotherapeutics and has been accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) since 2008. As a shared resource within the Center for Cellular Immunotherapies (CCI) and the Division of Transfusion Medicine & Therapeutic Pathology, the CVPF supports numerous investigational new drug (IND) protocols having developed the first successful FDA-approved CAR-T therapy and first-in-human CRISPR-edited T cells. Current protocols target a variety of disease indications (primarily HIV, adult and pediatric cancers, and autoimmune disorders). Many more trials are in development and once approved will further expand the scope of diseases targeted for cell and gene therapy.
Contact
Don L. Siegel, MD, PhD
CVPF Director
SiegelD@pennmedicine.upenn.edu
The CRISPR/Cas9 Mouse Targeting Core Facility serves to streamline procedures that facilitate investigators' use of the CRISPR/Cas9 genome editing technology for the rapid and economic generation of novel mouse genetic tool. Services offered: KO mice, KI mice - small sequences, CKO mice, KI mice - large sequences.
Contacts
Jorge Henao-Mejia, MD, PhD
Scientific Director
JHena@pennmedicine.upenn.edu
Leonel Joannas
Technical Director
LJoannas@pennmedicine.upenn.edu
Penn Cytomics and Cell Sorting SRL is the sole flow cytometry shared resource laboratory (SRL) at the University of Pennsylvania. Our facility has 35+ instruments, which include analyzers and cell sorters, several of which have spectral and imaging capabilities. We also have a dual-fluorescence cell counter/viability instrument and a tissue dissociator for cell preparation. We provide both on-site and off-site support to our instrument users, including analyzer and cell sorter training. We also have a research and development team that collaborates/consults with principal investigators in developing high-dimensional panels, as well as staining, acquisition, and analysis. Penn Cytomics is an Abramson Cancer Center supported facility and has been recognized as "exceptional" by the National Cancer Center for over 30 years.
Publishing or presenting Cytomics data? We appreciate you citing our core facility, as this helps us track scientific impact and provides justification for maintenance/future expansion of our facility. Suggested verbiage:
"The data for this (manuscript or presentation) were generated in the Penn Cytomics and Cell Sorting Shared Resource Laboratory at the University of Pennsylvania (RRID:SCR_022376). Penn Cytomics is partially supported by the Abramson Cancer Center NCI Grant (P30 016520)."
Contacts
Derek D. Jones, PhD
Senior Technical Director
JonesDer@pennmedicine.upenn.edu
William (Bill) Murphy
Technical Director
William.Murphy@pennmedicine.upenn.edu
The High-throughput Screening Core (HTSC), a joint effort of the Department of Pathology and Laboratory Medicine, the Department of Biochemistry and Biophysics, and the Department of Systems Pharmacology and Translational Therapeutics in partnership with the Perelman School of Medicine, provides expertise and infrastructure to facilitate the development and implementation of professional High-throughput screening services. We have the capabilities to perform HTS in both biochemical and cell-based assays using state-of-the-art equipment. We can perform genetic or small molecule screens to identify genes or small molecule modulators of diverse processes in diverse models including primary cells. The HTSC educates and assists scientists with HTS assay development, optimization, miniaturization, implementation, analysis, and validation. We can develop new assays or run validated HTS assays. In addition, the HTSC maintains libraries of siRNA, shRNA, cDNA, and FDA-approved/FDA-like organic small molecule libraries for HTS. Moreover, we routinely prepare custom libraries for single-point or dose-response screening. The HTSC provides robotics infrastructure and technically trained staff for primary HTSs as well as secondary screens to validate candidates. The HTSC also provides assistance with the preparation of grant applications and Letters of Support, offering HTS resources and analysis expertise for the proposed research.
The Human Immunology Core provides expertise and instrumentation for the analysis of immune function in patients during treatment with anticancer drugs and immunotherapy. The Core serves as a central facility for incorporating the newest technologies and performing validated immunology assays for phase I/II clinical studies, while also offering expert scientific and technical consultations to users interested in conducting this kind of innovative research.
Current services include:
- Multiplex Bead Arrays (e.g., luminex) which allow the simultaneous characterization of multiple cytokines or other biomarkers
- Digital ELISA (Quanterix HDX) for high-sensitivity protein detection
- Serology assays by ELISA, electrochemiluminescence or cell-based assay (e.g., ANA)
- Immune repertoire profiling (BCR & TCR sequencing with bulk or single cell platforms)
- Flow-cytometry based immunophenotyping and proliferation (CFSE) assays
- Cellular assays such as B and T cell ELISpot
- Primary lymphocyte isolation and sub-population enrichment from HLA-typed leukapheresis donors
- Processing, viable cryopreservation and banking of cells (e.g., blood, PBMCs, tumor samples etc.) and fluids (serum, plasma, CSF etc.) for clinical trial mechanistic assays
- QC, processing, analysis and visualization of immunology data including immune repertoire, single cell RNA-seq, luminex and flow cytometry
Please contact the Core for consultations for projects, method selection, clinical trial sample collection, budget preparation and letters of collaboration for grant proposals when designing your project. Please cite our RRID number when acknowledging the Core in your publications: RRID: SCR_022380.
Contacts
Nina Luning Prak, MD, PhD
Scientific Director
215-746-5768
Luning@pennmedicine.upenn.edu
Honghong Sun, PhD
Technical Director
215-573-4322
HSun2@pennmedicine.upenn.edu
As medicine charts new technological frontiers, such as bioinformatics, translational medicine and targeted therapies, notions of tissue and biospecimen banking are rapidly evolving. Biobanking is on the forefront, allowing researchers to utilize resources such as paraffin-archives. Biospecimen repositories will ultimately function as cores for discovery of information essential to improving patient care. In a combined effort, the Abramson Cancer Center and the Department of Pathology and Laboratory Medicine have a shared vision that will provide investigators the resources and organizational capabilities to maximize the potential of using tissue and other biospecimens for basic and translational research. In addition to undertaking tissue and biospecimen banking, the core will also work to define data driven standards for tissue and biospecimen banking practices at Penn.
The Tumor Tissue and Biospecimen Bank (TTAB) will create an extensive and robust bio-specimen and data repository by integrating multidisciplinary efforts of Cancer Center and other University of Pennsylvania Investigators. The facility will not only bank de-identified bio-specimens, while providing bioinformatics capabilities. Access will be determined by research protocols. Investigators’ banking efforts and data will be unified through a new sophisticated web-enabled database that is currently being customized. Investigators will use this database to easily identify and request material, regardless of physical location.
The TTAB is a sub-core of the Recruitment Outcomes and Assessment Resource at the Abramson Cancer Center. Later in 2026, TTAB will transition to the PCSC umbrella as the Tissue Based Research Core (TBRC).